Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372:1427–35.

Article  CAS  PubMed  Google Scholar 

Germain DP, Arad M, Burlina A, Elliott PM, Falissard B, Feldt-Rasmussen U, Hilz MJ, Hughes DA, Ortiz A, Wanner C, Weidemann F, Spada M. The effect of enzyme replacement therapy on clinical outcomes in female patients with fabry disease - A systematic literature review by a European panel of experts. Mol Genet Metab. 2019;126:224–35.

Article  CAS  PubMed  Google Scholar 

Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416–27.

Article  CAS  PubMed  Google Scholar 

Najafian B, Silvestroni A, Sokolovskiy A, Tøndel C, Svarstad E, Obrisca B, Ismail G, Holida MD, Mauer M. A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with fabry disease. Kidney Int. 2022;102:173–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fuller M, Mellett N, Hein LK, Brooks DA, Meikle PJ. Absence of α-galactosidase cross-correction in fabry heterozygote cultured skin fibroblasts. Mol Genet Metab. 2015;114:268–73.

Article  CAS  PubMed  Google Scholar 

Beck M, Cox TM, Comment. Why are females with fabry disease affected? Mol Genet Metab Rep. 2019;21:100529.

PubMed  PubMed Central  Google Scholar 

Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E. Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with fabry disease. Orphanet J Rare Dis. 2016;11:88.

Article  PubMed  PubMed Central  Google Scholar 

Martins AM, Cabrera G, Molt F, Suárez-Obando F, Valdés RA, Varas C, Yang M, Politei JM. The clinical profiles of female patients with fabry disease in Latin America: a Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status. JIMD Rep. 2019;49:107–17.

PubMed  PubMed Central  Google Scholar 

Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome Study Group. Ann Intern Med. 1994;121:953–9.

Article  CAS  PubMed  Google Scholar 

Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A. A validated disease severity scoring system for fabry disease. Mol Genet Metab. 2010;99:283–90.

Article  CAS  PubMed  Google Scholar 

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. CKD-EPI (chronic kidney disease epidemiology collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.

Article  PubMed  PubMed Central  Google Scholar 

Biegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, Rudnicki M, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, Tøndel C, Vujkovac B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE. Recommendations for initiation and cessation of enzyme replacement therapy in patients with fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.

Article  PubMed  PubMed Central  Google Scholar 

Üçeyler N, Ganendiran S, Kramer D, Sommer C. Characterization of pain in fabry disease. Clin J Pain. 2014;30:915–20.

Article  PubMed  Google Scholar 

Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, Baehner F, Kim K, Bajbouj M, Schwarting A, Gal A, Beck M. The Mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65:299–307.

Article  CAS  PubMed  Google Scholar 

Mehta A, Ginsberg L, FOS Investigators. Natural history of the cerebrovascular complications of fabry disease. Acta Paediatr Suppl. 2005;94:24–7.

Article  CAS  PubMed  Google Scholar 

Hopkin RJ, Cabrera GH, Jefferies JL, Yang M, Ponce E, Brand E, Feldt-Rasmussen U, Germain DP, Guffon N, Jovanovic A, Kantola I, Karaa A, Martins AM, Tøndel C, Wilcox WR, Yoo HW, Burlina AP, Mauer M. Clinical outcomes among young patients with fabry disease who initiated agalsidase beta treatment before 30 years of age: an analysis from the Fabry Registry. Mol Genet Metab. 2023;138:106967.

Article  CAS  PubMed  Google Scholar 

Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R. FOS European investigators. Effects of enzyme replacement therapy on pain and health related quality of life in patients with fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet. 2005;42:247–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whybra C, Miebach E, Mengel E, Gal A, Baron K, Beck M, Kampmann C. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with fabry disease. Genet Med. 2009;11:441–9.

Article  CAS  PubMed  Google Scholar 

Schiffmann R, Bichet DG, Jovanovic A, Hughes DA, Giugliani R, Feldt-Rasmussen U, Shankar SP, Barisoni L, Colvin RB, Jennette JC, Holdbrook F, Mulberg A, Castelli JP, Skuban N, Barth JA, Nicholls K. Migalastat improves diarrhea in patients with fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet J Rare Dis. 2018;13:68.

Article  PubMed  PubMed Central  Google Scholar 

Müntze J, Lau K, Cybulla M, Brand E, Cairns T, Lorenz L, Üçeyler N, Sommer C, Wanner C, Nordbeck P. Patient reported quality of life and medication adherence in fabry disease patients treated with migalastat: a prospective, multicenter study. Mol Genet Metab. 2023;138:106981.

Article  PubMed  Google Scholar 

Hughes D, Linhart A, Gurevich A, Kalampoki V, azukeviciene D, Feriozzi S, et al. FOS Study Group. Prompt agalsidase alfa therapy initiation is associated with improved renal and cardiovascular outcomes in a Fabry Outcome Survey analysis. Drug Des Devel Ther. 2021;15:3561–72.

Article  PubMed  PubMed Central  Google Scholar 

Parini R, Pintos-Morell G, Hennermann JB, Hsu TR, Karabul N, Kalampoki V, FOS Study Group, et al. Analysis of renal and cardiac outcomes in male participants in the Fabry Outcome Survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age. Drug Des Devel Ther. 2020;14:2149–58.

Article  PubMed  PubMed Central  Google Scholar 

Linhart A, Germain DP, Olivotto I, Akhtar MM, Anastasakis A, Hughes D, Namdar M, Pieroni M, Hagège A, Cecchi F, Gimeno JR, Limongelli G, Elliott P. An expert consensus document on the management of cardiovascular manifestations of fabry disease. Eur J Heart Fail. 2020;22:1076–96.

Article  PubMed  Google Scholar 

Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP, ESC Scientific Document Group. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44:3503–26.

Article  CAS  PubMed  Google Scholar 

Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT. Fabry Outcome Survey investigators. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet. 2009;374:1986–96.

Article  CAS  PubMed  Google Scholar 

Waas T, Schulz A, Lotz J, Rossmann H, Pfeiffer N, Beutel ME, Schmidtmann I, Münzel T, Wild PS, Lackner KJ. Distribution of estimated glomerular filtration rate and determinants of its age dependent loss in a German population-based study. Sci Rep. 2021;11:10165.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim JH, Lee BH, Hyang Cho J, Kang E, Choi JH, Kim GH, Yoo HW. Long-term enzyme replacement therapy for fabry disease: efficacy and unmet needs in cardiac and renal outcomes. J Hum Genet. 2016;61:923–9.

Article  CAS  PubMed  Google Scholar 

Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, Shankar S, Nedd K, Olivotto I, Ortiz D, Ohashi T, Hamazaki T, Skuban N, Yu J, Barth JA, Nicholls K. Long-term efficacy and safety of migalastat treatment in fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020;131:219–28.